Evidence map›Paper›PMID 30675426›Full record

ReviewKidney international supplements2017

Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action.

Aminu K Bello, Mona Alrukhaimi, Gloria E Ashuntantang, Shakti Basnet, Ricardo C Rotter, Walter G Douthat, Rumeyza Kazancioglu, Anna Köttgen, Masaomi Nangaku, Neil R Powe and 3 more

2 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Kidney international supplements, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 123 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 5 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04229485 unknown statusnot on this mapstarted 2020, after this paper: background citation

The Chinese Cohort Study of Chronic Kidney Disease Patients Followed on Smartphone Platform, a Multi-center Observational Study

TypeobservationalSponsorLimeng ChenRan2020 to 2023Enrolled3,360ConditionsChronic Kidney Diseases
NCT06963853 recruitingnot on this mapstarted 2022, after this paper: background citation

Evaluation of Microbial and Endocrinological Parameters in Dialysis Patients With Sepsis

TypeobservationalSponsorWestern Galilee Hospital-NahariyaRan2022 to 2027Enrolled200ConditionsSepsis, HemodialysisArmsBlood cultures will be obtained from three sources: 1. The central venous catheter (CVC), 2. The dialysis machine circuit, and 3. A peripheral vein
3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 5 syntheses or guidelines pooled it, 249 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 11 countries.

Aminu K BelloDepartment of Medicine, Division of Nephrology & Immunology, University of Alberta, Edmonton, Alberta, Canada.
Mona AlrukhaimiDepartment of Medicine, Dubai Medical College, Dubai, United Arab Emirates.
Gloria E AshuntantangFaculty of Medicine and Biomedical Sciences, Yaounde General Hospital, University of Yaounde I, Yaounde, Cameroon.
Shakti BasnetDepartment of Nephrology, Gautam Buddha Community Kidney Center, Butwal, Nepal.
Ricardo C RotterDepartment of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zuibrán, Mexico City, Mexico.
Walter G DouthatServicio de Nefrologia, Hospital Privado-Universitario de Cordoba, and Instituto Universitario de Ciencias Biomédicas, Cordoba, Argentina.
Rumeyza KazanciogluDivision of Nephrology, Bezmialem Vakif University, Istanbul, Turkey.
Anna KöttgenInstitute of Genetic Epidemiology, Medical Center and Faculty of Medicine -University of Freiburg, Freiburg, Germany.
Masaomi NangakuDepartment of Hemodialysis and Apheresis, Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Neil R PoweDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Sarah L WhiteCharles Perkins Centre, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
David C WheelerCentre for Nephrology, Royal Free Hospital, University College London, London, UK.
Orson MoeDepartment of Internal Medicine and Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Bezmiâlem Vakıf Üniversitesi · TRDubai Medical College · AEHospital Privado · ARInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXSan Francisco General Hospital · USThe Royal Free Hospital · GBThe University of Sydney · AUThe University of Texas Southwestern Medical Center · USThe University of Tokyo · JPUniversité de Yaoundé I · CMUniversity of Alberta · CAUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The International Society of Nephrology has adopted a proactive approach to defining the current state of kidney care and unmet needs through a multifaceted Closing the Gaps initiative. As part of this initiative, the International Society of Nephrology convened a meeting of experts to develop an approach to tackle acute kidney injury and chronic kidney disease (CKD). This manuscript expands on the recently published International Society of Nephrology CKD Roadmap and reports on the discussions of the working group assigned to the task of reviewing the global impact of complication of CKD. The working group defined the following goals: Goal 1: Optimize the management of anemia and endocrine and metabolic abnormalities associated with CKD. The impact of these conditions at a global level is not well understood, particularly in regions where renal replacement therapy is not readily available. Some treatment regimens may be affordable in low- and middle-income countries and if implemented, could have an impact on the burden of suffering associated with CKD. Goal 2: Improve the prevention and management of cardiovascular complications linked to CKD. Most research on cardiovascular complications of CKD has focused on atherosclerotic diseases (myocardial infarction, ischemic stroke, and peripheral gangrene). There has been growing recognition that other forms of cardiovascular diseases, such as heart failure, valvular disease and arrhythmias, have a major impact on patient outcomes. Much less is known about the mechanisms and treatment of these non-atherosclerotic complications. Goal 3: Improve the diagnosis and management of symptoms associated with CKD. Symptom management is one of the greatest challenges in the management of CKD, with limited knowledge about the mechanisms associated with the development of these common problems and how best to characterize them into usable clinical phenotypes. Improved understanding of the complications of CKD may alleviate suffering and prolong life among millions of people worldwide both in developed countries and in regions where renal replacement therapy is not widely available.

Indexed as

CKDcomplicationsknowledge gapsmanagementmechanisms

Identifiers

PMID30675426
PMCPMC6341007
OpenAlexW2754289264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.